Abstract
Introduction

44
Influenza viruses are highly contagious respiratory pathogens that pose a constant threat 45 throughout the world. In addition to annual epidemics, influenza A viruses can potentially cause 46 pandemics, when the new virus differs antigenically from previously circulating variants, so that the 47 human population is immunologically naïve. The global spread of various subtypes of influenza A 48 viruses in birds provides the preconditions for interspecies transmission: the past two decades have seen 49 an increase in the number of cases of human infection with avian influenza viruses H5, H7 and H9 [1] [2] [3] .
50
One of the most important initiatives to prepare for an influenza pandemic is focused on developing and 51 evaluating appropriate vaccines. Different approaches and platforms have been used to develop vaccines 52 against potentially pandemic influenza viruses and, over the past few years, a large body of data has 53 been accumulated on the safety and immunogenicity of these vaccines. The latest summary of clinical 54 trials of potential pandemic vaccines can be found on the WHO website [4] .
55
This pandemic preparedness plan uses a strain-specific approach, in which candidate vaccine 56 viruses are prepared against the pathogens thought most likely to cause the next pandemic. However, as significance, are rather weak immunogens; classical approaches to immunization are not capable of (cHA) that contain an identical stalk domain (for example, from the H1N1 virus), but in which the 73 globular domains vary significantly in antigenicity, i.e. belong to different subtypes of influenza A 74 viruses [12, 13] . Several recent studies have demonstrated that live attenuated influenza vaccines (LAIVs) 75 expressing chimeric HAs are capable of inducing cross-reactive HA stalk-specific antibodies, either 76 when used as a priming vaccine followed by inactivated influenza vaccine (IIV) [14, 15] , or when several 77 cHA-based LAIVs are administered sequentially to mice. With sequential immunization with two or 78 three doses of LAIV, mice were better protected against heterologous challenge infection when the 79 vaccines had the same HA stalk domain, compared with vaccines that contained intact HA [16] . It was, 80 therefore, considered important to test the same vaccination regimen in a ferret model, the most suitable 81 animal model for studying influenza infection [17] .
82
Another promising approach for designing broadly protective influenza vaccines is the 83 development of immunogens that induce strong T-cell immunity, which is known to be cross-reactive 84 among antigenically different viruses [18] [19] [20] . Although T-cell immunity does not prevent influenza 85 infection, there is evidence that T cells can recognize the conserved epitopes of viral proteins, reduce 86 viral load and alleviate symptoms in animals and humans after infection with heterologous influenza 87 viruses [21] [22] [23] [24] . LAIVs are believed to be good inducers of virus-specific cytotoxic CD8+ T-cell 88 immunity [25] [26] [27] [28] [29] . Therefore, sequential immunization with cHA-containing LAIVs should not only 89 induce broadly protective stalk-specific antibodies, but also stimulate cross-reactive T-cell immunity.
90
However, the cytotoxic T-cell (CTL) immunity induced by licensed LAIVs might be 91 suboptimal in protecting against currently circulating influenza viruses, because the nucleoprotein (NP)
92
and M1 protein, known as the most immunodominant targets for CTL immunity, originate from master 93 donor virus isolated over 60 years ago [30, 31] . Even though these proteins are relatively conserved 94 among different subtypes of influenza A viruses, they are still subject to slow evolutionary changes [32] .
95
Over the past 20 years, a large number of studies have indicated that certain immunodominant T-cell 96 epitopes have disappeared as the influenza viruses have evolved [33] [34] [35] . The mutations in the epitopes 97 mean that CTLs targeted to the original, non-mutated epitopes will be inefficient in detecting virus-98 infected cells [36] . This problem can be partially solved by replacing the NP gene in the genome of the 99 LAIV virus by one from a currently circulating influenza virus. Indeed, recently we showed that 100 engineering of LAIV reassortants with 5:3 genome compositions induced CTL responses that were more 101 relevant to current infections [36] [37] [38] .
A high dose of challenge virus was used in order to evaluate the vaccines' ability to reduce influenza 107 virus-induced pathology.
109
Materials and Methods
110
Viruses and proteins
111
The LAIV reassortant viruses used in this study are shown in A/mallard/Sweden/24/02 (H8N4) and A/quail/Hong Kong/G1/1997 (H9N2) were generated as 117 described previously [16] . RG plasmids bearing control non-chimeric full-length HAs of the H5N1,
118
H8N4 and H9N2 viruses were also generated as in the previous study [16] . The three groups of LAIV 
Ferret immunization and challenge
Four groups of seven ferrets were inoculated intranasally with three doses of LAIV viruses or 167 phosphate-buffered saline (PBS) placebo at 21-day intervals, as illustrated in Figure 1 . The vaccine 168 viruses were administered in a dose of 7.0 log10EID50 and an inoculum of 0.5 ml. 
Virological methods
184
Virus replication in the ferrets' respiratory tract was assessed by endpoint titration of NFW, lung 185 and trachea specimens in embryonated chicken eggs. Tenfold sample dilutions were inoculated into 10-186 11-day-old eggs and incubated at 33 °C for 72 hours. Virus titers were expressed as log10EID50/ml for 187 NFW and log10EID50/gram for trachea and lung specimens. 
Pathology studies
226
At the time of necropsy, a complete macroscopic (gross pathology) examination was performed.
227
The nasal turbinates (NT), trachea and lungs were studied in detail, and the abdominal and pelvic 228 cavities were examined. Tissue sections of nasal turbinates, trachea and left cranial and left caudal lung 229 lobes were taken from each sacrificed animal on day 4 post-challenge and used for histological analysis.
230
After fixation in 10% buffered formalin, lungs were embedded in paraffin and prepared for 231 histopathological analysis. For nasal turbinates and trachea, after fixation in formalin the specimens 232 were decalcified in Gooding-Stewart fluid (a mixture of 25% concentrated formic acid, 5% formalin 233 solution and 75% distilled water) for 14 days and then embedded in paraffin and prepared for 234 histopathological analysis. Tissue sections of 5 µm were prepared and stained with Alcian blue at pH 235 2.5, followed by hematoxylin and eosin staining to reveal goblet cells on microscopic examination. For 236 the assessment of fibrin deposition, sections of lungs were stained with picro-Mallory stain [42] .
237
Infection pathology was evaluated as described elsewhere [43] , including indicators of damage to the 238 epithelial lining and acute inflammation. The damage to lung tissues was scored using epithelial NFW specimens and tissues of ferrets was assessed using the Mann-Whitney U-test. Differences in log2-254 transformed HI and ELISA antibody titers were also subjected to the Mann-Whitney U-test. P values of 255 <0.05 were considered significant. 26 °C did not exceed 3.0 log10EID50). These data suggest that the source of the NP gene in the LAIV 270 virus could affect the ca phenotype. However, the effect is strain-specific, as the other stalk-based (Table 2) . In the three groups of ferrets given vaccine, no significant differences were observed in clinical On day 63, HAI antibody titers against a panel of influenza A viruses were low ( Figure 4A ).
Results
258
Virological characterization of LAIV viruses used in the study
323
The only significant increase was seen for the anti-H9N2 HAI antibody in the LAIVs (NP-MDV) group.
324
In contrast, much higher titers of serum IgG antibodies were detected. Thus, when an H5N2 LAIV 325 whole virus was used as antigen, the IgG antibody titers exceeded 1:1024 in all three vaccine groups,
326
indicating that the immunizations were successful ( Figure 4B ). Significant rises in IgG titers were also 327 seen for the recombinant H8 and H9 protein antigens, which also indicates successful immunization, as 328 all the vaccine groups included reassortant viruses containing the HA head domains from H8N4 and 329 H9N2 viruses. Although the H2N2 hemagglutinin belongs to the same group as the H5, H8 and H9
330
HAs, there was no significant increase in anti-H2 antibody titers in the sera of immunized ferrets ( Figure   331 4B). Importantly, significant titers of IgG antibodies reacting with chimeric cH6/1 protein were detected 332 only in the two immunization groups given cHA-containing LAIVs ( Figure 4B ). 
376
Scores for clinical signs for each ferret during the four days after the challenge. * Significant difference 377 from the mock-vaccinated group (Mann-Whitney U test).
379 380
Body temperature
381
The body temperature of the ferrets in the challenge phase is shown in Figure 7A . There was a 382 significant difference between all three vaccine groups and the control group in the maximal delta T 383 parameter ( Figure 7B ), suggesting that the vaccinated animals were protected against severe fever.
384
However, in terms of the area under the curve, the only significant difference was between the cHA 385 LAIVs (NP-WT) group and the controls ( Figure 7C ). These data suggest that, while all vaccine 386 regimens reduced fever similarly, the duration of fever was significantly shorter in animals that received
387
LAIVs containing chimeric HA and WT NP. hemorrhages and alveolar emphysema were defined ( Figure 9A ).
435
In the cHA LAIVs (NP-WT) group, morphological changes included minimal or slight Figure 9A ).
446
In conclusion, all groups of vaccinated animals showed fewer pathological changes and a lower Table 2 .
452
Overall, the universal LAIV candidates expressing cHAs and WT NP were the most effective of 453 the LAIVs tested in this trial against a high-dose heterologous virus challenge. H1N1pdm09 virus.
487
The rationale for including recent NP in the LAIV genome composition has been discussed in the 488 context of our previous studies in a mouse model [37, 38] , and in in vitro study of human donor peripheral 489 blood mononuclear cells [36] . In this ferret study, for the first time the two strategies for enhancing the LAIVs with classical NP.
493
In vitro characterization of the LAIV viruses showed that they all preserved the ts phenotype, schedule is safe, regardless of the LAIV virus composition tested in the trial.
507
In contrast to our previous mouse study [16] with our previous findings in mice [16] and with reports of other authors [14, 15] .
516
The main purpose of this trial was to determine whether the replacement of the HA and NP genes and WT NP protected against pulmonary virus replication. It should be noted that all three vaccine groups showed reduced pulmonary virus titers, and the fact that the decreases in the other two vaccine 537 groups were not significant may be related to the small number of ferrets in each group.
538
A recent study by Nachbagauer et al. [14, 15] found that a cHA LAIV prime followed by a cHA IIV 
562
The primary limitation of this study is that T-cell immunity was not analyzed for the immunized 563 ferrets. This was because of a lack of well-defined reagents and protocols for this animal model.
564
Although several recent studies have established protocols and suggested the use of specific antibodies, Program ID 0557-2016-0013 (histopathology study).
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